Fresenius Nod In EU Adds To Crowded Adalimumab Market

 
• By Dave Wallace

Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.

Crowd
Fresenius Kabi Has Joined The Adalimumab Crowd • Source: Shutterstock

More from Biosimilars

More from Products